Ascrinvacumab

Names

[ Name ]:
Ascrinvacumab

Biological Activity

[Description]:

Ascrinvacumab (PF-03446962) is a human IgG2 monoclonal antibody targets ALK-1. Ascrinvacumab shows binding efficiency with human ALK1 with a Kd value of 7 nM. Ascrinvacumab can be used for the research of hepatocellular carcinoma (HCC)[1].

[Related Catalog]:

Research Areas >> Cancer

Signaling Pathways >> Protein Tyrosine Kinase/RTK >> ALK

[In Vitro]

Ascrinvacumab 与细胞人 ALK1 结合，Kd 值为 7 nm[1]。 Ascrinvacumab (30 分钟) 阻断 BMP9 和 FCS 诱导的应答，缓解 BMP9 诱导的 Smad1 磷酸化强度和持续时间[1]。 Ascrinvacumab (0.01-10 μg/mL; 2 h) 抑制 BMP9 结合到 ALK1[1]。 Ascrinvacumab (40 μg/mL; 2 h) 有效抑制人脐静脉内皮细胞 (HUVECs) 的内皮萌发[1]。

[In Vivo]

Ascrinvacumab 联合贝伐单抗 (bevacizumab; anti-VEGF) 可降低人血管密度，提高抗肿瘤疗效在小鼠嵌合体肿瘤模型中[1]。

[References]

[1]. van Meeteren LA, et al. Anti-human activin receptor-like kinase 1 (ALK1) antibody attenuates bone morphogenetic protein 9 (BMP9)-induced ALK1 signaling and interferes with endothelial cell sprouting. J Biol Chem. 2012 May 25;287(22):18551-61.

Chemical & Physical Properties

No Any Chemical & Physical Properties

Related Compounds

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.